HK1096022A1 - Combination therapy with azd-2171[73] astrazeneca ab s-151 85 södertälje sweden - Google Patents

Combination therapy with azd-2171[73] astrazeneca ab s-151 85 södertälje sweden

Info

Publication number
HK1096022A1
HK1096022A1 HK07103004.1A HK07103004A HK1096022A1 HK 1096022 A1 HK1096022 A1 HK 1096022A1 HK 07103004 A HK07103004 A HK 07103004A HK 1096022 A1 HK1096022 A1 HK 1096022A1
Authority
HK
Hong Kong
Prior art keywords
azd2171
taxane
södertälje
azd
astrazeneca
Prior art date
Application number
HK07103004.1A
Other languages
English (en)
Inventor
Stephen Robert Wedge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1096022A1 publication Critical patent/HK1096022A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK07103004.1A 2004-03-23 2007-03-20 Combination therapy with azd-2171[73] astrazeneca ab s-151 85 södertälje sweden HK1096022A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0406445.7A GB0406445D0 (en) 2004-03-23 2004-03-23 Combination therapy
PCT/GB2005/001089 WO2005092385A2 (en) 2004-03-23 2005-03-22 Combination therapy of azd2171 and a taxane

Publications (1)

Publication Number Publication Date
HK1096022A1 true HK1096022A1 (en) 2007-05-25

Family

ID=32188481

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07103004.1A HK1096022A1 (en) 2004-03-23 2007-03-20 Combination therapy with azd-2171[73] astrazeneca ab s-151 85 södertälje sweden

Country Status (19)

Country Link
US (1) US20070135462A1 (de)
EP (1) EP1729807B1 (de)
JP (1) JP2007530520A (de)
KR (1) KR20070008651A (de)
CN (1) CN1997396A (de)
AT (1) ATE447973T1 (de)
AU (1) AU2005225197B2 (de)
BR (1) BRPI0508983A (de)
CA (1) CA2558598A1 (de)
DE (1) DE602005017590D1 (de)
ES (1) ES2335291T3 (de)
GB (1) GB0406445D0 (de)
HK (1) HK1096022A1 (de)
IL (1) IL177953A0 (de)
MX (1) MXPA06010757A (de)
NO (1) NO20064754L (de)
NZ (1) NZ549554A (de)
WO (1) WO2005092385A2 (de)
ZA (1) ZA200607554B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
CA2558346A1 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy
US20090176731A1 (en) * 2005-07-06 2009-07-09 Stephen Robert Wedge Combination therapy of cancer with azd2171 and gemcitabine
WO2007071970A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of azd2171 and pemetrexed
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
CA2250295C (en) * 1996-03-12 2008-12-30 Pg-Txl Company L.P. Water soluble paclitaxel prodrugs
US6596712B2 (en) * 1996-04-26 2003-07-22 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
EP1024833A1 (de) * 1996-07-11 2000-08-09 Farmarc Nederland B.V. Pharmazeutische zusammensetzung mit saurem zusatzsalz der basischen droge
CZ306810B6 (cs) * 1999-02-10 2017-07-19 Astrazeneca Ab Použití chinazolinového derivátu jako inhibitoru angiogeneze
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ATE369894T1 (de) * 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
RU2350618C2 (ru) * 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent
GB0316123D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
GB0316127D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
CA2558346A1 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
WO2006035203A1 (en) * 2004-09-27 2006-04-06 Astrazeneca Ab Cancer combination therapy comprising azd2171 and imatinib
US20090176731A1 (en) * 2005-07-06 2009-07-09 Stephen Robert Wedge Combination therapy of cancer with azd2171 and gemcitabine
EP3168234A1 (de) * 2005-12-15 2017-05-17 Medimmune Limited Kombination eines angiopoetin-2-antagonisten und eines vegf-a, kdr- und/oder fltl-antagonisten zur behandlung von krebs
WO2007071970A2 (en) * 2005-12-22 2007-06-28 Astrazeneca Ab Combination of azd2171 and pemetrexed

Also Published As

Publication number Publication date
BRPI0508983A (pt) 2007-08-28
DE602005017590D1 (de) 2009-12-24
CA2558598A1 (en) 2005-10-06
GB0406445D0 (en) 2004-04-28
IL177953A0 (en) 2006-12-31
AU2005225197B2 (en) 2008-10-09
KR20070008651A (ko) 2007-01-17
WO2005092385A2 (en) 2005-10-06
ATE447973T1 (de) 2009-11-15
WO2005092385A3 (en) 2006-11-02
EP1729807A2 (de) 2006-12-13
AU2005225197A1 (en) 2005-10-06
MXPA06010757A (es) 2006-12-15
ZA200607554B (en) 2008-05-28
CN1997396A (zh) 2007-07-11
NZ549554A (en) 2009-12-24
US20070135462A1 (en) 2007-06-14
NO20064754L (no) 2006-10-20
EP1729807B1 (de) 2009-11-11
JP2007530520A (ja) 2007-11-01
ES2335291T3 (es) 2010-03-24

Similar Documents

Publication Publication Date Title
HK1078771A1 (en) Use of the quinazoline derivative zd6474 combined with gemcitabine and optionally ionising radiationin the treatment of cancer
MX2007003506A (es) Terapia de combinacion de cancer que comprende azd2171 e imatinib.
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
IL191796A0 (en) Combination of zd6474 and pemetrexed
MX2007005356A (es) Terapia de combinacion que comprende zd6474 y un antiadrogenico.
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
HK1096023A1 (en) Combination therapy with azd2171 and 5-fu and/or cpt-11 azd2171?5-fu?cpt-11
HK1096022A1 (en) Combination therapy with azd-2171[73] astrazeneca ab s-151 85 södertälje sweden
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
ZA200600188B (en) Combination therapy
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140322